Arrowhead Pharmaceuticals (ARWR) Declines -25.65% Over 30 Days Despite Strong Clinical Pipeline
Key Takeaways
- Arrowhead Pharmaceuticals (ARWR) fell about 25.65% over the trailing 30 days, from a close of $89.41 to $66.48, despite a steady stream of positive clinical updates.
- The decline followed a powerful rally, with the stock still up more than 110% over the trailing 12 months, underscoring profit-taking and fading short-term momentum.
- Positive Phase 3 plozasiran data and encouraging early ARO-DIMER-PA results were outweighed by a broad de-risking of high-multiple biotech names and rising Treasury yields.
- Analyst coverage remains constructive, with several firms maintaining Buy or Outperform ratings and price targets well above the recent close.
Arrowhead Pharmaceuticals (ARWR) Company Overview and Market Position
Arrowhead Pharmaceuticals is a Pasadena, California-based biopharmaceutical company that develops RNA interference (RNAi) medicines designed to silence disease-causing genes. Its proprietary Targeted RNAi Molecule (TRiM) platform is built to deliver therapies to tissues including the liver, lungs, and skeletal muscle.
The company's first commercial product, plozasiran (marketed as REDEMPLO), is approved in the United States, the European Union, and Australia for familial chylomicronemia syndrome (FCS). Arrowhead is pursuing label expansion into severe hypertriglyceridemia (sHTG) and advancing a pipeline spanning cardiovascular, metabolic, pulmonary, and neurological diseases. High-value partnerships with AstraZeneca, Johnson & Johnson, Sarepta, Novartis, and others provide milestone and royalty revenue. Investors follow the stock for its pipeline breadth, its transition to commercial-stage operations, and its emerging cardiometabolic franchise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Arrowhead Pharmaceuticals (ARWR) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30-day window, ARWR declined from $89.41 to $66.48, a drop of roughly 25.65%. The move was backloaded, with the shares holding near their highs through late August before selling off sharply in September, including a decline of about 12% on September 15 and a further pullback the following session.
The three-month picture shows a similar reversal. From a level near $81.82 in mid-June, the stock is down approximately 18.75% over the quarter after reaching a 52-week high near $95 during the summer rally. The broader trend has shifted from strong upward momentum into consolidation and profit-taking, even as the stock remains substantially higher on a trailing 12-month basis.
What Drove ARWR Stock Price in the Last 30 Days
Several overlapping factors shaped the recent decline. On August 30-31, Arrowhead presented 12-month Phase 3 results from the SHASTA-3 and SHASTA-4 trials of plozasiran in sHTG at the European Society of Cardiology Congress. Both studies met their primary endpoints, with median triglyceride reductions of 79% and 81%, respectively, and more than 90% of treated patients reaching levels below 500 mg/dL. The company also reported fewer acute pancreatitis events and said it plans to file a supplemental New Drug Application by the end of 2026 using a Priority Review Voucher.
On September 15, Arrowhead reported interim Phase 1/2a data for ARO-DIMER-PA, its first dual-target RNAi candidate for mixed hyperlipidemia, showing simultaneous reductions in PCSK9 and APOC3 alongside meaningful declines in LDL cholesterol and triglycerides.
Despite these results, the shares sold off, reflecting profit-taking after a strong run, a "sell-the-news" reaction to early single-dose data, and a sector-wide risk-off move. Pressure was amplified by a failed cardiovascular trial from Novartis (NVS) and a sharp decline in Amgen (AMGN), which spilled over into gene-silencing names such as Alnylam (ALNY). Rising Treasury yields and renewed rate-hike expectations further weighed on long-duration, pre-profitability biotech valuations. From what I see, this sector rotation played a bigger role than the company-specific news.
Analyst sentiment stayed supportive even as the stock fell, with Citi initiating coverage at Buy with a $108 target and J.P. Morgan, RBC Capital, and HC Wainwright reiterating bullish ratings with targets ranging from $100 to $120.
What Drove ARWR Stock Performance Over the Last Quarter
The quarter's narrative was a rally followed by a reversal. ARWR climbed to a 52-week high in late July on positive topline Phase 3 results from the SHASTA-3 and SHASTA-4 studies, which bolstered confidence in plozasiran's commercial launch and label-expansion opportunity. Detailed 12-month results presented in late August reinforced that optimism.
As momentum faded in September, however, the stock gave back a substantial portion of those gains as investors locked in profits and rotated away from richly valued growth names amid rising rates and sector volatility. The net result was a stock still materially higher on a trailing 12-month basis but lower over the most recent quarter.
ARWR Stock Forecast Drivers: What Investors Should Watch Next
Investors are likely to focus on several upcoming catalysts. Initial human data for ARO-MAPT, Arrowhead's tau-targeting candidate for Alzheimer's disease and related tauopathies, was expected around late September or early October. The planned sNDA filing for plozasiran in sHTG and the ongoing REDEMPLO launch in FCS are key commercial milestones, while multidose data for ARO-DIMER-PA is anticipated at a future medical conference. Later-stage updates for the ARO-INHBE and ARO-ALK7 metabolic programs are expected toward year-end.
Macroeconomic factors, including interest-rate expectations and risk appetite for high-multiple biotech stocks, will also remain relevant given ARWR's sensitivity to those dynamics. Investors should monitor clinical readouts, regulatory decisions, and commercial execution rather than rely on short-term price momentum. I’m watching this closely as the next set of data could shift sentiment again.
Exploring AI Tools for Biotech Analysis
In my own research process, I often review Tickeron's Trending AI Robots page to see how automated strategies are positioned around names like Arrowhead Pharmaceuticals. The section highlights top-performing bots across different strategies and timeframes, which can offer an additional quantitative lens when evaluating biotech volatility and sector rotation. It serves as a practical starting point for data-driven ideas without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
ARWR sees MACD Histogram just turned negative
ARWR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 39 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In 80 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
ARWR moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARWR crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ARWR entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in 229 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.161) is normal, around the industry mean (25.951). P/E Ratio (48.719) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (436.793).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs to treat intractable diseases
Industry Biotechnology
Advertisement